Information Provided By: 
Fly News Breaks for December 21, 2016
FLXN
Dec 21, 2016 | 16:51 EDT
Raymond James analyst Elliot Wilbur initiated Flexion with a Strong Buy and a $35 price target. Flexion is developing a novel and durable injectable product candidate known as Zilretta, an intra-articular formulation of approved corticosteroid triamcinolone acetonide. The analyst believes, based on positive Phase III clinical data, Zilretta could become a first-line option for patients in need of meaningful safe and longer-lasting pain relief.
News For FLXN From the Last 2 Days
There are no results for your query FLXN
